<DOC>
	<DOCNO>NCT00903682</DOCNO>
	<brief_summary>The purpose study compare neuropsychiatric adverse event profile etravirine 400mg daily versus efavirenz 600mg daily , combination 2 N ( ) RTIs , approximately 150 treatment-na√É-ve HIV-1 infected patient . Safety , tolerability efficacy treatment arm assess throughout study .</brief_summary>
	<brief_title>A Clinical Trial Comparing Tolerability Etravirine Efavirenz Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors Treatment-naive HIV-1 Infected Patients</brief_title>
	<detailed_description>This phase IIb , randomise ( study medication assign chance ) , double-blind ( neither patient study physician know treatment group patient assign ) trial ass neuropsychiatric adverse event profile etravirine ( ETR ) 400mg daily versus efavirenz ( EFV ) 600mg daily , combination investigator-selected background 2 anti-HIV drug class nucleoside/nucleotide reverse transcriptase inhibitor ( N [ ] RTIs ) . The combination N [ ] RTIs chosen study physician abacavir ( ABC ) /lamivudine ( 3TC ) , zidovudine ( AZT ) /lamivudine ( 3TC ) tenofovir disoproxil fumarate ( TDF ) /emtricitabine ( FTC ) . Approximately 150 Human Immuno-deficiency Virus type 1 ( HIV-1 ) infect patient , never receive antiretroviral ( ARV ) treatment randomly assign ( like toss coin ) either etravirine treatment group control group ( efavirenz ) . The study period include screening period maximum 6 week , 48 week treatment period , additional 2-8 week treatment unblinding ( study physician ( patient ) receive information treatment group patient assign ) , follow 4 week follow-up period . The main purpose study gather data many , often , severe central nervous system psychiatric ( neuropsychiatric ) event two treatment group . In addition , study look overall safety , tolerability antiviral effectiveness two treatment group . During trial , patient ' health monitor physical examination , check vital sign ( blood pressure / pulse ) , laboratory test blood urine sample . Also blood sample draw measure antiviral effectiveness ( i.e. , decrease plasma viral load level &lt; 50 HIV-1 RNA ( ribonucleic acid ) copies/mL ) , immunology assessment ( ass body 's immune system ) pharmacokinetic ( measure drug level blood ) analysis etravirine . Patients ask complete `` HIV Patient Symptoms Profile '' ( HIV PSP ) Questionnaire visit , contain question relate impact patient ' current health well-being . The study hypothesis proportion patient least one neuropsychiatric adverse event relate study drug , observed start treatment ( Baseline ; BSL ) Week 12 , significantly low etravirine group efavirenz group . Patients take blinded medication twice day , administer orally ( mouth ) . Only one blind dos contain active ingredient . Etravirine 400mg ( dummy-pills ) - 4 tablet - take day , follow meal , preferably breakfast . Efavirenz 600mg ( dummy-pill ) - 1 tablet - administer daily empty stomach , preferably bedtime.The intake investigator-selected N [ ] RTIs take instructed investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Documented HIV1 infection In judgement investigator , appropriate initiate ARV therapy base patient medical condition take account applicable guideline treatment HIV1 infection Patient access investigatorselected ARV regimen poststudy accordance applicable guideline treatment HIV1 infection HIV1 plasma viral load screen &gt; = 5000 HIV1 RNA ( copies/ml ) Predicted phenotypic sensitivity currently approve NNRTIs N ( ) RTIs background regimen screen Any previous treatment therapeutic HIV vaccine use ARVs , include use NVP prevention vertical HIV transmission The presence least one mutation specific indicator transmit ( primary ) drug resistance Known infection HIV2 HIV1 group O Category C AIDS define illness , except stable Kaposi 's Sarcoma , waste syndrome progressive Pneumocystis jiroveci/carinii Pneumonia ( PCP ) consider cure Specific grade 3 4 laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Intelence</keyword>
	<keyword>etravirine</keyword>
	<keyword>ETR</keyword>
	<keyword>TMC125</keyword>
	<keyword>Sustiva</keyword>
	<keyword>efavirenz</keyword>
	<keyword>EFV</keyword>
	<keyword>Non-nucleoside Reverse Transcriptase Inhibitor</keyword>
	<keyword>NNRTI</keyword>
	<keyword>treatment-naive</keyword>
</DOC>